Answer
LOQTORZI (toripalimab), combined with cisplatin and gemcitabine, is indicated for first-line treatment of adults with recurrent nasopharyngeal carcinoma not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma.
Sources for this answer
- LOQTORZI 240 mg concentrate for solution for infusionTopalliance Biosciences Europe Limited · emc · SmPC §4.1 Therapeutic Indications · Version 1Document updated
Sources checked